Oncolix derived its technologies from the Greenville Health System in 2007. Wen Chen, the inventor of Prolanta, also invented Somavert, a growth hormone antagonist now sold by Pfizer for the treatment of acromegaly.
GHS is a leading provider and innovator of cancer treatment in the southeastern USA. This research institution has more than 9000 employees, including 1000 MDs.
GHS is currently the largest (but not the majority) shareholder of Oncolix. Their organization has invested more than $7 million into Oncolix.
MD Anderson has consistently been ranked the No. 1 hospital for cancer care in the nation, most recently by US News & World Report’s “Best Hospitals” survey. This institution also ranks first in the number and amount of research grants awarded by the National Cancer Institute.
MD Anderson discovered the mechanism of action of Prolanta (autophagy) through a sponsored research program with a world renowned researcher, Anil Sood, MD. MD Anderson announced this finding at an American Association of Cancer Research meeting (click here for poster) and later published the results in CELL (click here for publication).
Oncolix is a member of BIO, the world’s largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide.
BioHouston is a non-profit corporation founded by Houston area academic and research institutions. Their mission is to establish the Houston region as a vigorous global competitor in the life science and biotechnology commercialization. Their mission is to create an environment that will stimulate technology transfer and research commercialization.
Oncolix welcomes interest in developing a technical or financial partnership with both public and private entities that are symbiotic and will allow Prolanta™ to reach the market. Contact us today.